NL301228I2 - nirsevimab - Google Patents

nirsevimab

Info

Publication number: NL301228I2
Authority: NL; Netherlands
Prior art keywords: nirsevimab
Prior art date: 2014-01-15

Application number

NL301228C

Other languages

English (en)

Other versions

NL301228I1 (nl

Original Assignee

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-15

Filing date

2023-04-26

Publication date

2023-09-13

2023-04-26 Application filed by Medimmune Ltd filed Critical Medimmune Ltd

2023-05-03 Publication of NL301228I1 publication Critical patent/NL301228I1/nl

2023-09-13 Publication of NL301228I2 publication Critical patent/NL301228I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NL301228C 2014-01-15 2023-04-26 nirsevimab NL301228I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461927819P	2014-01-15	2014-01-15
PCT/US2015/011391 WO2015108967A2 (en)	2014-01-15	2015-01-14	Rsv-specific antibodies and functional parts thereof

Publications (2)

Publication Number	Publication Date
NL301228I1 NL301228I1 (nl)	2023-05-03
NL301228I2 true NL301228I2 (nl)	2023-09-13

Family

ID=53543612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301228C NL301228I2 (nl)	2014-01-15	2023-04-26	nirsevimab

Country Status (26)

Country	Link
US (5)	US20160340414A1 (nl)
EP (3)	EP3741390A1 (nl)
JP (3)	JP6836398B2 (nl)
KR (1)	KR102188437B1 (nl)
CN (2)	CN116355080A (nl)
AU (3)	AU2015206570A1 (nl)
CA (1)	CA2933200A1 (nl)
CY (2)	CY1123425T1 (nl)
DK (1)	DK3094353T3 (nl)
ES (1)	ES2795727T3 (nl)
FI (1)	FIC20230016I1 (nl)
FR (1)	FR23C1016I1 (nl)
HK (1)	HK1225992A1 (nl)
HR (1)	HRP20200607T1 (nl)
HU (2)	HUE048855T2 (nl)
LT (2)	LT3094353T (nl)
MX (1)	MX2016008639A (nl)
NL (1)	NL301228I2 (nl)
NO (1)	NO2023016I1 (nl)
PL (1)	PL3094353T3 (nl)
PT (1)	PT3094353T (nl)
RS (1)	RS60387B1 (nl)
SI (1)	SI3094353T1 (nl)
SM (1)	SMT202000282T1 (nl)
TW (1)	TWI705974B (nl)
WO (1)	WO2015108967A2 (nl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
HUE048855T2 (hu)	2014-01-15	2020-08-28	Medimmune Llc	RSV-re specifikus ellenanyagok és azok funkcionális részei
EP3529272A2 (en)	2016-10-21	2019-08-28	Adimab, LLC	Anti-respiratory syncytial virus antibodies, and methods of their generation and use
TWI761453B (zh)	2017-03-01	2022-04-21	英商梅迪繆思有限公司	抗rsv單株抗體配製物
SG11202007241WA (en) *	2018-01-31	2020-08-28	Wistar Inst	Nucleic acid antibody constructs for use against respiratory syncytial virus
CN111606993B (zh) *	2019-02-26	2022-06-28	中国科学院上海生命科学研究院	抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用
US12024553B2 (en)	2019-04-30	2024-07-02	Medimmune Limited	Dosage regimens for and compositions including anti-RSV antibodies
CA3229901A1 (en)	2021-09-13	2023-03-16	Medimmune Limited	Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab
CN116987183B (zh) *	2022-07-22	2024-10-15	北京智仁美博生物科技有限公司	抗呼吸道合胞病毒中和性抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU2005302453A1 (en) *	2004-10-29	2006-05-11	Medimmune, Llc	Methods of preventing and treating RSV infections and related conditions
CA2587766A1 (en) *	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
PL2486941T3 (pl) *	2006-10-02	2017-08-31	E. R. Squibb & Sons, L.L.C.	Przeciwciała ludzkie wiążące cxcr4 i ich wykorzystanie
MX2009009226A (es) *	2007-03-06	2009-10-28	Symphogen As	Anticuerpos recombinantes para el tratamiento de infecciones con el virus respiratorio sincitial.
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
EP2069400A4 (en) *	2007-06-26	2012-03-07	Medimmune Llc	METHOD FOR THE TREATMENT OF RSV INFECTIONS AND RELATED DISEASES
US8092804B2 (en) *	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
BRPI0906490A2 (pt)	2008-01-15	2015-07-14	Abbott Lab	Vetores de expressão de mamífero melhorados e uso dos mesmos
US9273118B2 (en) *	2009-07-15	2016-03-01	Aimm Therapeutics B.V.	Means and methods for producing high affinity antibodies
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
RU2540020C2 (ru) *	2009-10-06	2015-01-27	Медиммьюн Лтд	Молекула, специфически связывающаяся с rsv
WO2011056697A1 (en) *	2009-10-28	2011-05-12	Medimmune, Llc	Topical methods of treating rsv infections and related conditions
US9228006B2 (en) *	2012-03-16	2016-01-05	University Health Network	Methods and compositions for modulating Toso activity
AU2013266340A1 (en) *	2012-05-22	2014-12-04	Shire Human Genetic Therapies, Inc.	Anti-CCL2 antibodies for treatment of scleroderma
AU2014212268B2 (en)	2013-02-01	2018-07-19	Medimmune, Llc	Respiratory Syncytial Virus F protein epitopes
HUE048855T2 (hu)	2014-01-15	2020-08-28	Medimmune Llc	RSV-re specifikus ellenanyagok és azok funkcionális részei
JP2020509025A (ja)	2017-03-01	2020-03-26	メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅＬｉｍｉｔｅｄ	モノクローナル抗体製剤
TWI761453B (zh)	2017-03-01	2022-04-21	英商梅迪繆思有限公司	抗rsv單株抗體配製物

2015
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en active Application Filing
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 MX MX2016008639A patent/MX2016008639A/es active IP Right Grant
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 CA CA2933200A patent/CA2933200A1/en active Pending
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Protection Beyond IP Right Term
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
2016
- 2016-12-21 HK HK16114507A patent/HK1225992A1/zh unknown
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-04-17 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 FR FR23C1016C patent/FR23C1016I1/fr active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-25 CY CY2023011C patent/CY2023011I1/el unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-28 LT LTPA2023514C patent/LTPA2023514I1/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown

Also Published As

Publication number	Publication date
US10689437B2 (en)	2020-06-23
US20200331989A1 (en)	2020-10-22
EP3741390A1 (en)	2020-11-25
PT3094353T (pt)	2020-06-08
ES2795727T3 (es)	2020-11-24
KR20160104018A (ko)	2016-09-02
JP6836398B2 (ja)	2021-03-03
SMT202000282T1 (it)	2020-07-08
EP3094353A2 (en)	2016-11-23
JP2020103293A (ja)	2020-07-09
EP4353316A2 (en)	2024-04-17
DK3094353T3 (da)	2020-06-02
CY2023011I2 (el)	2023-11-15
WO2015108967A3 (en)	2015-09-03
CA2933200A1 (en)	2015-07-23
BR112016015044A2 (pt)	2017-09-19
EP3094353A4 (en)	2017-09-06
AU2020203831A1 (en)	2020-07-02
FR23C1016I1 (fr)	2023-06-23
TWI705974B (zh)	2020-10-01
EP4353316A3 (en)	2024-08-21
HK1225992A1 (zh)	2017-09-22
HUS2300019I1 (hu)	2023-05-28
WO2015108967A2 (en)	2015-07-23
SI3094353T1 (sl)	2020-07-31
US20230365660A1 (en)	2023-11-16
JP2017504321A (ja)	2017-02-09
RU2016133247A (ru)	2018-02-20
CN105916520A (zh)	2016-08-31
KR102188437B1 (ko)	2020-12-08
WO2015108967A8 (en)	2015-10-01
US20160340414A1 (en)	2016-11-24
LTPA2023514I1 (nl)	2023-05-25
AU2021204339A1 (en)	2021-07-22
BR112016015044A8 (pt)	2023-04-11
MX2016008639A (es)	2017-02-15
NO2023016I1 (no)	2023-04-25
RU2016133247A3 (nl)	2019-01-16
AU2021204339B2 (en)	2024-11-14
FIC20230016I1 (fi)	2023-04-26
US11661449B2 (en)	2023-05-30
PL3094353T3 (pl)	2020-09-07
RS60387B1 (sr)	2020-07-31
US12173050B2 (en)	2024-12-24
US11186628B2 (en)	2021-11-30
CN116355080A (zh)	2023-06-30
JP2023052693A (ja)	2023-04-11
LT3094353T (lt)	2020-08-10
CY2023011I1 (el)	2023-11-15
AU2015206570A1 (en)	2016-07-14
CY1123425T1 (el)	2021-12-31
EP3094353B1 (en)	2020-04-01
US20220098285A1 (en)	2022-03-31
TW201612191A (en)	2016-04-01
NL301228I1 (nl)	2023-05-03
HRP20200607T1 (hr)	2020-07-10
HUE048855T2 (hu)	2020-08-28
US20190106482A1 (en)	2019-04-11

Publication	Publication Date	Title
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da)	2021-10-25	Karadgang
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
EP3230438C0 (en)	2024-12-04	N-GLYCOSYLATION
NL301228I2 (nl)	2023-09-13	nirsevimab
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement
DK3009858T3 (da)	2021-08-09	Skyradar
DK3447493T3 (da)	2020-08-17	Proteinrettede ortologer
ES1133830Y (es)	2015-02-12	Columbario
DK3091875T3 (da)	2019-10-14	Vipbar taburet
DE202014005655U8 (de)	2014-11-13	llluminationsvorrichtung
DE112015005055A5 (de)	2017-08-03	Gargerätevorrichtung
DK3191825T3 (da)	2019-05-06	Kreatininbiosensor
FI10894U1 (fi)	2015-06-11	Putkieristyskouru
ES1136185Y (es)	2015-09-03	Huevera
FI10806U1 (fi)	2015-03-13	Ajoestepylväs
FI10861U1 (fi)	2015-04-30	Liukumisenestonasta